Latest & greatest articles for pulmonary embolism

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pulmonary embolism or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pulmonary embolism and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pulmonary embolism

121. Diagnostic accuracy of magnetic resonance angiography for acute pulmonary embolism - a systematic review and meta-analysis. (PubMed)

Diagnostic accuracy of magnetic resonance angiography for acute pulmonary embolism - a systematic review and meta-analysis. The aim of this meta-analysis was to evaluate the diagnostic accuracy of magnetic resonance angiography (MRA) for acute pulmonary embolism (PE).A systematic literature search was conducted that included studies from January 2000 to August 2015 using the electronic databases PubMed, Embase and Springer link. The summary receiver operating characteristic (SROC) curve

Full Text available with Trip Pro

2016 VASA. Zeitschrift fur Gefasskrankheiten

122. Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism (PubMed)

Oral and inhaled corticosteroid use and risk of recurrent pulmonary embolism Chronic inflammatory diseases predispose for development of a first pulmonary embolism (PE). Previous studies showed that corticosteroids, which are the mainstay of treatment for inflammatory diseases, enhance the risk of a first venous thromboembolism. Yet, it is unknown whether corticosteroids also predispose for recurrent events. Therefore, we investigated the association between oral and/or inhaled corticosteroid

2016 EvidenceUpdates

123. Investigation and treatment of pulmonary embolism as a potential etiology may be important to improve post‐resuscitation prognosis in non‐shockable out‐of‐hospital cardiopulmonary arrest: report on an analysis of the SOS‐KANTO 2012 study (PubMed)

Investigation and treatment of pulmonary embolism as a potential etiology may be important to improve post‐resuscitation prognosis in non‐shockable out‐of‐hospital cardiopulmonary arrest: report on an analysis of the SOS‐KANTO 2012 study The prognosis of non-shockable out-of-hospital cardiac arrest is worse than that of shockable out-of-hospital cardiac arrest. We investigated the associations between the etiology and prognosis of non-shockable out-of-hospital cardiac arrest patients (...) and 3 months between various etiological and presumed cardiac factors. The proportion of the favorable brain function patients that developed pulmonary embolism or incidental hypothermia was significantly higher than that of the patients with presumed cardiac factors (1 month, P < 0.0001 and P < 0.0001, respectively; 3 months, P = 0.0018 and P < 0.0001, respectively). In multiple logistic regression analysis, pulmonary embolism and incidental hypothermia were found to be significant independent

Full Text available with Trip Pro

2016 Acute medicine & surgery

124. Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score (PubMed)

Effectiveness of prognosticating pulmonary embolism using the ESC algorithm and the Bova score The prognostic value of the European Society of Cardiology (ESC) 2014 algorithm and the Bova score has lacked adequate validation. According to the ESC 2014 guidelines and the Bova score, we retrospectively risk stratified normotensive patients with PE who were enrolled in the PROTECT study. This study used a complicated course (which consisted of death from any cause, haemodynamic collapse (...) , or recurrent PE) as the primary endpoint, and follow-up occurred through 30 days after the PE diagnosis. Of 848 patients, 37 % had a sPESI of 0 and 5 (1.6 %; 95 % confidence interval [CI], 0.5-3.7 %) experienced a complicated course. Of 143 patients with a sPESI of 0 points and negative computed tomographic pulmonary angiography (CTPA) for right ventricle (RV) dysfunction, three (2.1 %; 95 % CI, 0.4-6.0 %) experienced a complicated course. Four hundred seventy-eight (56 %) patients with a sPESI ≥ 1 had

2016 EvidenceUpdates

125. Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE): a case report (PubMed)

Pulmonary embolism in an adolescent girl with negative ACLA systemic lupus erythematosus (SLE): a case report Pulmonary involvement is a common manifestation in systemic lupus erythematosus (SLE), whereas pulmonary thromboembolism (PTE) is rarely seen in SLE. PTE related to anti-phospholipid antibody syndrome (APS) is also a rare disease. We have reported a 13-year-old female diagnosed with SLE Two years ago, who is being treated with hydroxychloroquine and prednisolone. She presented (...) with shortness of breath, dry cough, and fever about two weeks prior to admission. She was initially admitted with the diagnosis of pneumonia, but no clinical improvement was seen she was given antibiotics. Hemoptysis was added to her symptoms, so spiral high resolution computed tomography (HRCT) of the lungs was requested, and it indicated patchy consolidations bilaterally. With suspicion of pulmonary thromboembolism (PTE), spiral computed tomography angiography of pulmonary vessels was done, revealing PTE

Full Text available with Trip Pro

2016 Electronic physician

126. Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy (PubMed)

Time trends and case fatality rate of in-hospital treated pulmonary embolism during 11 years of observation in Northwestern Italy Pulmonary embolism (PE) is a common disorder with high mortality and morbidity rates. However, population-based information on its incidence and prognosis remains limited. We conducted a large epidemiology study collecting data on hospitalisation for PE (from 2002 to 2012) in a population of about 13 million people in Northwestern Italy. Patients were identified

2016 EvidenceUpdates

127. Anticoagulant treatment for subsegmental pulmonary embolism. (PubMed)

Anticoagulant treatment for subsegmental pulmonary embolism. Acute pulmonary embolism (PE) is a common cause of death, accounting for 50,000 to 200,000 deaths annually. It is the third most common cause of mortality among the cardiovascular diseases, after coronary artery disease and stroke.The advent of multi-detector computed tomographic pulmonary angiography (CTPA) has allowed better assessment of PE regarding visualisation of the peripheral pulmonary arteries, increasing its rate (...) PEs. However, the clinical significance in patients and their prognosis have to be studied to evaluate whether anticoagulation therapy is required.This review is an update of a Cochrane systematic review first published in 2014.To assess the effectiveness and safety of anticoagulation therapy versus no intervention in patients with isolated subsegmental pulmonary embolism (SSPE) or incidental SSPE.The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched

2016 Cochrane

128. Suspected Pulmonary Embolism

Suspected Pulmonary Embolism Revised 2016 ACR Appropriateness Criteria® 1 Suspected Pulmonary Embolism American College of Radiology ACR Appropriateness Criteria ® Suspected Pulmonary Embolism Variant 1: Suspected pulmonary embolism. Intermediate probability with a negative D-dimer or low pretest probability. Radiologic Procedure Rating Comments RRL* X-ray chest 9 ? CTA chest with IV contrast 5 This procedure should be optimized for pulmonary arterial enhancement. This procedure may (...) contrast 2 O US echocardiography transthoracic resting 2 O CT chest without and with IV contrast 1 ??? Arteriography pulmonary with right heart catheterization 1 ???? MRA chest without IV contrast 1 O US echocardiography transesophageal 1 O Rating Scale: 1,2,3 Usually not appropriate; 4,5,6 May be appropriate; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Suspected Pulmonary Embolism Variant 2: Suspected pulmonary embolism. Intermediate probability with a positive

2016 American College of Radiology

129. Formative assessment and design of a complex clinical decision support tool for pulmonary embolism

Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Formative assessment and design of a complex clinical decision support tool for pulmonary embolism | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Formative assessment and design of a complex clinical decision support tool for pulmonary embolism Article Text Methods Formative assessment and design of a complex clinical decision

2016 Evidence-Based Medicine

130. Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy?

Should Patients Who Receive a Diagnosis of Acute Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy? TAKE-HOME MESSAGE There is evidence to suggest a small mortality bene?t with the administration of thrombolytics for hemodynamically stable pulmonary embolism patients with right ventricular strain, but this bene?t must be weighed against the signi?cantly increased risk of major bleeding. Should Patients Who Receive a Diagnosis of Acute (...) Pulmonary Embolism and Have Evidence of Right Ventricular Strain Be Treated With Thrombolytic Therapy? EBEM Commentator Melinda J. Morton, MD, MPH Department of Emergency Medicine Johns Hopkins University School of Medicine Baltimore, MD Results Commentary Previous systematic reviews have not consistently reported a reduc- tioninmortalitywiththrombolytic therapy for an unselected popula- tion of patients with pulmonary embolism. 2 The American Heart Association currently recommends that providers

2016 Annals of Emergency Medicine Systematic Review Snapshots

131. Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death?

Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Sufficient Sensitivity to Identify Patients at Very Low Risk of Death? Systematic Review Snapshot TAKE-HOME MESSAGE Five pulmonary embolism clinical prediction rules to predict early all-cause mortality have sensitivities greater than 88%, but only 3 are supported by a high level of evidence. The simpli?ed Pulmonary Embolism Severity Index appears to have the greatest potential, given its relatively higher sensitivity and ease (...) of use. Do Clinical Prediction Rules for Acute Pulmonary Embolism Have Suf?cient Sensitivity to Identify Patients at Very Low Risk of Death? EBEM Commentators Brit J. Long, MD Department of Emergency Medicine SAUSHEC Fort Sam Houston, TX Alex Koyfman, MD Department of Emergency Medicine UT Southwestern Medical Center/Parkland Memorial Hospital Dallas, TX Results Thesystematicreviewidenti?ed 40 studies reporting on 11 different clinical prediction rules, with the majorityreportingonasinglerule;4

2016 Annals of Emergency Medicine Systematic Review Snapshots

132. Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates?

Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ?trigger rates? Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal (...) accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Avoiding alert fatigue in pulmonary embolism decision support: a new method to examine ‘trigger rates’ Article Text Original EBM Research Avoiding alert fatigue in pulmonary embolism

2016 Evidence-Based Medicine

133. Risk factors of pulmonary embolism in injured patients - a systematic review

Risk factors of pulmonary embolism in injured patients - a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

134. Thrombolytic therapy in pulmonary embolism: a clinical risk-benefit analysis

Thrombolytic therapy in pulmonary embolism: a clinical risk-benefit analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

135. A systematic review of the interventions aiming at reducing overdiagnosis and the overuse of diagnostic imaging in the emergency department and inpatient settings when a pulmonary embolism is suspected

A systematic review of the interventions aiming at reducing overdiagnosis and the overuse of diagnostic imaging in the emergency department and inpatient settings when a pulmonary embolism is suspected Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files

2016 PROSPERO

136. Prognostic significance of right heart thrombi in patients with acute symptomatic pulmonary embolism: systematic review and meta-analysis

Prognostic significance of right heart thrombi in patients with acute symptomatic pulmonary embolism: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

137. Treatments for massive and submassive pulmonary embolism: a systematic review

Treatments for massive and submassive pulmonary embolism: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect

2016 PROSPERO

138. Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. (PubMed)

Oral direct thrombin inhibitors or oral factor Xa inhibitors for the treatment of pulmonary embolism. Pulmonary embolism is a potentially life-threatening condition in which a clot can travel from the deep veins, most commonly in the leg, up to the lungs. Previously, a pulmonary embolism was treated with the anticoagulants heparin and vitamin K antagonists. Recently, however, two forms of direct oral anticoagulants (DOACs) have been developed: oral direct thrombin inhibitors (DTI) and oral (...) of pulmonary embolism.The Cochrane Vascular Trials Search Co-ordinator searched the Specialised Register (last searched January 2015) and the Cochrane Register of Studies (last searched January 2015). Clinical trials databases were also searched for details of ongoing or unpublished studies. We searched the reference lists of relevant articles retrieved by electronic searches for additional citations.We included randomised controlled trials in which patients with a pulmonary embolism confirmed by standard

Full Text available with Trip Pro

2015 Cochrane

139. Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months?

Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? BestBets: Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Is long-term Rivaroxaban superior to Warfarin in pulmonary embolism at 6 months? Report By: Chris Morgan - Medical Student Y5 Search checked by Rick Body - Consultant in Emergency Medicine Institution: University of Manchester, Manchester, UK Original institution: Manchester Royal Infirmary Date Submitted: 21st October 2015 (...) Date Completed: 21st October 2015 Last Modified: 21st October 2015 Status: Green (complete) Three Part Question In [patients with proven pulmonary embolism (PE)] is [Rivaroxaban better than warfarin] at [reducing mortality and recurrence of venous thromboembolism at 6 months]? Clinical Scenario A 52-year-old lady has presented to the Emergency Department with a suspected PE. This is confirmed by CT pulmonary angiography (CTPA). Consequently she requires anticoagulation. Hospital guidelines suggest

2015 BestBETS

140. Thrombolytic therapy for pulmonary embolism. (PubMed)

Thrombolytic therapy for pulmonary embolism. Thrombolytic therapy (powerful anticoagulation drugs) is usually reserved for patients with clinically serious or massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may dissolve blood clots more rapidly than heparin and reduce the death rate associated with PE. However, there are still concerns about the possible risk of adverse effects of thrombolytic therapy, such as major or minor haemorrhages. This is the second update (...) pulmonary embolism compared with heparin. Furthermore, thrombolytic therapies included in the review were heterogeneous. Thrombolytic therapy may be helpful in reducing the recurrence of pulmonary emboli but may cause more major and minor haemorrhagic events and stroke. More high quality double blind RCTs assessing safety and cost-effectiveness are required.

Full Text available with Trip Pro

2015 Cochrane